Enliven Therapeutics, Inc. (ELVN) — Total Assets
| Fiscal Year | Total Assets | Change YoY |
|---|---|---|
| 2025 | $476.17M | +46.2% |
| 2024 | $325.76M | +19.8% |
| 2023 | $271.87M | +226.4% |
| 2022 | $83.30M | -11.1% |
| 2021 | $93.65M | +3.1% |
| 2020 | $90.84M | +172.8% |
| 2019 | $33.30M | — |
| Fiscal Year | Total Assets | Change YoY |
|---|---|---|
| 2025 | $476.17M | +46.2% |
| 2024 | $325.76M | +19.8% |
| 2023 | $271.87M | +226.4% |
| 2022 | $83.30M | -11.1% |
| 2021 | $93.65M | +3.1% |
| 2020 | $90.84M | +172.8% |
| 2019 | $33.30M | — |